转移检测assay验证:活检基因表达改善根治性放疗前列腺癌风险分层
研究在248例接受根治性放疗联合雄激素剥夺治疗的前列腺癌患者诊断活检中独立验证70基因转移检测assay。
要点
- 10年无转移生存率assay阳性72% vs 阴性94%(HR=3.21,P=0.003)
- 多因素分析中assay对远处转移独立预测(HR=2.71,P=0.030)
- 与CAPRA联合时assay独立预后(HR=3.23,P=0.019),CAPRA不显著
核心结论
- 转移检测assay在根治性放疗患者中显示显著预后性能,独立于标准临床病理变量。
- 该assay可能有助于高危患者治疗强化的决策。
研究设计与样本
- 研究先建立桥接队列优化转移检测assay阈值,再在独立验证队列中评估。
- 独立验证队列包含248例接受根治性放疗和雄激素剥夺治疗的前列腺癌患者诊断活检标本。
- 采用多因素Cox比例风险回归分析评估assay对生化失败无生存(BFFS)和无转移生存(MFS)的预测性能。
临床怎么用
- 转移检测assay可用于根治性放疗前高危前列腺癌患者的风险分层。
- assay结果可能辅助决定是否进行治疗强化。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy is an effective treatment of intermediate/high-risk locally advanced prostate cancer, however, >30% of patients relapse within 5 years. Clinicopathological parameters currently fail to identify patients prone to systemic relapse and those whom treatment intensification may be beneficial. The purpose of this study was to independently validate the performance of a 70-gene Metastatic Assay in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy. PATIENTS AND METHODS: A bridging cohort of prostate cancer diagnostic biopsy specimens was profiled to enable optimization of the Metastatic Assay threshold before further independent clinical validation in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy. Multivariable Cox proportional hazard regression analysis was used to assess assay performance in predicting biochemical failure-free survival (BFFS) and metastasis-free survival (MFS). RESULTS: Gene expression analysis was carried out in 248 patients from the independent validation cohort and the Metastatic Assay applied. Ten-year MFS was 72% for Metastatic Assay positive patients and 94% for Metastatic Assay negative patients [HR = 3.21 (1.35-7.67); P = 0.003]. On multivariable analysis the Metastatic Assay remained predictive for development of distant metastases [HR = 2.71 (1.11-6.63); P = 0.030]. The assay retained independent prognostic performance for MFS when assessed with the Cancer of the Prostate Assessment Score (CAPRA) [HR = 3.23 (1.22-8.59); P = 0.019] whilst CAPRA itself was not significant [HR = 1.88, (0.52-6.77); P = 0.332]. A high concordance [100% (61.5-100)] for the assay result was noted between two separate foci taken from 11 tumours, whilst Gleason score had low concordance. CONCLUSIONS: The Metastatic Assay demonstrated significant prognostic performance in patients treated with radical radiotherapy both alone and independent of standard clinical and pathological variables. The Metastatic Assay could have clinical utility when deciding upon treatment intensification in high-risk patients. Genomic and clinical data are available as a public resource.
引用
- Jain S, Lyons CA, Walker SM, et al. Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Ann Oncol. 2018. PMID: 29045551. doi:10.1093/annonc/mdx637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。